Search

Your search keyword '"Van Rossum, Michelle M."' showing total 194 results
Start Over Author "Van Rossum, Michelle M."
194 results on '"Van Rossum, Michelle M."'

1. Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial

Author

Bol, Kalijn F., Schreibelt, Gerty, Bloemendal, Martine, van Willigen, Wouter W., Hins-de Bree, Simone, de Goede, Anna L., de Boer, Annemiek J., Bos, Kevin J. H., Duiveman-de Boer, Tjitske, Olde Nordkamp, Michel A. M., van Oorschot, Tom G. M., Popelier, Carlijn J., Pots, Jeanne M., Scharenborg, Nicole M., van de Rakt, Mandy W. M. M., de Ruiter, Valeska, van Meeteren, Wilmy S., van Rossum, Michelle M., Croockewit, Sandra J., Koeneman, Bouke J., Creemers, Jeroen H. A., Wortel, Inge M. N., Angerer, Caroline, Brüning, Mareke, Petry, Katja, Dzionek, Andrzej, van der Veldt, Astrid A., van Grünhagen, Dirk J., Werner, Johanna E. M., Bonenkamp, Johannes J., Haanen, John B. A. G., Boers-Sonderen, Marye J., Koornstra, Rutger H. T., Boomsma, Martijn F., Aarntzen, Erik H. J., Gotthardt, Martin, Nagarajah, James, de Witte, Theo J. M., Figdor, Carl G., de Wilt, Johannes H. W., Textor, Johannes, de Groot, Jan Willem B., Gerritsen, Winald R., and de Vries, I. Jolanda M.

Published
2024
Full Text
View/download PDF

2. Adjuvant dendritic cell therapy in stage IIIB/C melanoma:the MIND-DC randomized phase III trial

Author

Bol, Kalijn F., Schreibelt, Gerty, Bloemendal, Martine, van Willigen, Wouter W., Hins-de Bree, Simone, de Goede, Anna L., de Boer, Annemiek J., Bos, Kevin J.H., Duiveman-de Boer, Tjitske, Olde Nordkamp, Michel A.M., van Oorschot, Tom G.M., Popelier, Carlijn J., Pots, Jeanne M., Scharenborg, Nicole M., van de Rakt, Mandy W.M.M., de Ruiter, Valeska, van Meeteren, Wilmy S., van Rossum, Michelle M., Croockewit, Sandra J., Koeneman, Bouke J., Creemers, Jeroen H.A., Wortel, Inge M.N., Angerer, Caroline, Brüning, Mareke, Petry, Katja, Dzionek, Andrzej, van der Veldt, Astrid A., van Grünhagen, Dirk J., Werner, Johanna E.M., Bonenkamp, Johannes J., Haanen, John B.A.G., Boers-Sonderen, Marye J., Koornstra, Rutger H.T., Boomsma, Martijn F., Aarntzen, Erik H.J., Gotthardt, Martin, Nagarajah, James, de Witte, Theo J.M., Figdor, Carl G., de Wilt, Johannes H.W., Textor, Johannes, de Groot, Jan Willem B., Gerritsen, Winald R., de Vries, I. Jolanda M., Bol, Kalijn F., Schreibelt, Gerty, Bloemendal, Martine, van Willigen, Wouter W., Hins-de Bree, Simone, de Goede, Anna L., de Boer, Annemiek J., Bos, Kevin J.H., Duiveman-de Boer, Tjitske, Olde Nordkamp, Michel A.M., van Oorschot, Tom G.M., Popelier, Carlijn J., Pots, Jeanne M., Scharenborg, Nicole M., van de Rakt, Mandy W.M.M., de Ruiter, Valeska, van Meeteren, Wilmy S., van Rossum, Michelle M., Croockewit, Sandra J., Koeneman, Bouke J., Creemers, Jeroen H.A., Wortel, Inge M.N., Angerer, Caroline, Brüning, Mareke, Petry, Katja, Dzionek, Andrzej, van der Veldt, Astrid A., van Grünhagen, Dirk J., Werner, Johanna E.M., Bonenkamp, Johannes J., Haanen, John B.A.G., Boers-Sonderen, Marye J., Koornstra, Rutger H.T., Boomsma, Martijn F., Aarntzen, Erik H.J., Gotthardt, Martin, Nagarajah, James, de Witte, Theo J.M., Figdor, Carl G., de Wilt, Johannes H.W., Textor, Johannes, de Groot, Jan Willem B., Gerritsen, Winald R., and de Vries, I. Jolanda M.

Abstract

Autologous natural dendritic cells (nDCs) treatment can induce tumor-specific immune responses and clinical responses in cancer patients. In this phase III clinical trial (NCT02993315), 148 patients with resected stage IIIB/C melanoma were randomized to adjuvant treatment with nDCs (n = 99) or placebo (n = 49). Active treatment consisted of intranodally injected autologous CD1c+ conventional and plasmacytoid DCs loaded with tumor antigens. The primary endpoint was the 2-year recurrence-free survival (RFS) rate, whereas the secondary endpoints included median RFS, 2-year and median overall survival, adverse event profile, and immunological response The 2-year RFS rate was 36.8% in the nDC treatment group and 46.9% in the control group (p = 0.31). Median RFS was 12.7 months vs 19.9 months, respectively (hazard ratio 1.25; 90% CI: 0.88−1.79; p = 0.29). Median overall survival was not reached in both treatment groups (hazard ratio 1.32; 90% CI: 0.73−2.38; p = 0.44). Grade 3−4 study-related adverse events occurred in 5% and 6% of patients. Functional antigen-specific T cell responses could be detected in 67.1% of patients tested in the nDC treatment group vs 3.8% of patients tested in the control group (p < 0.001). In conclusion, while adjuvant nDC treatment in stage IIIB/C melanoma patients generated specific immune responses and was well tolerated, no benefit in RFS was observed.

Published
2024

3. Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial

Author

Boudewijns, Steve, Bloemendal, Martine, de Haas, Nienke, Westdorp, Harm, Bol, Kalijn F., Schreibelt, Gerty, Aarntzen, Erik H. J. G., Lesterhuis, W. Joost, Gorris, Mark A. J., Croockewit, Alexandra, van der Woude, Lieke L., van Rossum, Michelle M., Welzen, Marieke, de Goede, Anna, Hato, Stanleyson V., van der Graaf, Winette T. A., Punt, Cornelis J. A., Koornstra, Rutger H. T., Gerritsen, Winald R., Figdor, Carl G., and de Vries, I. Jolanda M.

Published
2020
Full Text
View/download PDF

5. Heterozygous missense variants of LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction

Author

Wesdorp, Mieke, de Koning Gans, Pia A. M., Schraders, Margit, Oostrik, Jaap, Huynen, Martijn A., Venselaar, Hanka, Beynon, Andy J., van Gaalen, Judith, Piai, Vitória, Voermans, Nicol, van Rossum, Michelle M., Hartel, Bas P., Lelieveld, Stefan H., Wiel, Laurens, Verbist, Berit, Rotteveel, Liselotte J., van Dooren, Marieke F., Lichtner, Peter, Kunst, Henricus P. M., Feenstra, Ilse, Admiraal, Ronald J. C., DOOFNL Consortium, Yntema, Helger G., Hoefsloot, Lies H., Pennings, Ronald J. E., and Kremer, Hannie

Published
2018
Full Text
View/download PDF

6. Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

Author

Westdorp, Harm, Creemers, Jeroen H. A., van Oort, Inge M., Schreibelt, Gerty, Gorris, Mark A. J., Mehra, Niven, Simons, Michiel, de Goede, Anna L., van Rossum, Michelle M., Croockewit, Alexandra J., Figdor, Carl G., Witjes, J. Alfred, Aarntzen, Erik H. J. G., Mus, Roel D. M., Brüning, Mareke, Petry, Katja, Gotthardt, Martin, Barentsz, Jelle O., de Vries, I. Jolanda M., and Gerritsen, Winald R.

Published
2019
Full Text
View/download PDF

7. Supplementary Table 1 from Route of Administration Modulates the Induction of Dendritic Cell Vaccine–Induced Antigen-Specific T Cells in Advanced Melanoma Patients

Author

Lesterhuis, W. Joost, primary, de Vries, I. Jolanda M., primary, Schreibelt, Gerty, primary, Lambeck, Annechien J.A., primary, Aarntzen, Erik H.J.G., primary, Jacobs, Joannes F.M., primary, Scharenborg, Nicole M., primary, van de Rakt, Mandy W.M.M., primary, de Boer, Annemiek J., primary, Croockewit, Sandra, primary, van Rossum, Michelle M., primary, Mus, Roel, primary, Oyen, Wim J.G., primary, Boerman, Otto C., primary, Lucas, Sophie, primary, Adema, Gosse J., primary, Punt, Cornelis J.A., primary, and Figdor, Carl G., primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figure 2 from Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients

Author

Aarntzen, Erik H. J. G., primary, Schreibelt, Gerty, primary, Bol, Kalijn, primary, Lesterhuis, W. Joost, primary, Croockewit, Alexandra J., primary, de Wilt, Johannes H. W., primary, van Rossum, Michelle M., primary, Blokx, Willeke A. M., primary, Jacobs, Joannes F. M., primary, Duiveman-de Boer, Tjitske, primary, Schuurhuis, Danita H., primary, Mus, Roel, primary, Thielemans, Kris, primary, de Vries, I. Jolanda M., primary, Figdor, Carl G., primary, Punt, Cornelis J. A., primary, and Adema, Gosse J., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure 3 from Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients

Author

Aarntzen, Erik H. J. G., primary, Schreibelt, Gerty, primary, Bol, Kalijn, primary, Lesterhuis, W. Joost, primary, Croockewit, Alexandra J., primary, de Wilt, Johannes H. W., primary, van Rossum, Michelle M., primary, Blokx, Willeke A. M., primary, Jacobs, Joannes F. M., primary, Duiveman-de Boer, Tjitske, primary, Schuurhuis, Danita H., primary, Mus, Roel, primary, Thielemans, Kris, primary, de Vries, I. Jolanda M., primary, Figdor, Carl G., primary, Punt, Cornelis J. A., primary, and Adema, Gosse J., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure 2 from Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells

Author

Schreibelt, Gerty, primary, Bol, Kalijn F., primary, Westdorp, Harm, primary, Wimmers, Florian, primary, Aarntzen, Erik H.J.G., primary, Duiveman-de Boer, Tjitske, primary, van de Rakt, Mandy W.M.M., primary, Scharenborg, Nicole M., primary, de Boer, Annemiek J., primary, Pots, Jeanette M., primary, Olde Nordkamp, Michel A.M., primary, van Oorschot, Tom G.M., primary, Tel, Jurjen, primary, Winkels, Gregor, primary, Petry, Katja, primary, Blokx, Willeke A.M., primary, van Rossum, Michelle M., primary, Welzen, Marieke E.B., primary, Mus, Roel D.M., primary, Croockewit, Sandra A.J., primary, Koornstra, Rutger H.T., primary, Jacobs, Joannes F.M., primary, Kelderman, Sander, primary, Blank, Christian U., primary, Gerritsen, Winald R., primary, Punt, Cornelis J.A., primary, Figdor, Carl G., primary, and de Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure 3 from Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells

Author

Schreibelt, Gerty, primary, Bol, Kalijn F., primary, Westdorp, Harm, primary, Wimmers, Florian, primary, Aarntzen, Erik H.J.G., primary, Duiveman-de Boer, Tjitske, primary, van de Rakt, Mandy W.M.M., primary, Scharenborg, Nicole M., primary, de Boer, Annemiek J., primary, Pots, Jeanette M., primary, Olde Nordkamp, Michel A.M., primary, van Oorschot, Tom G.M., primary, Tel, Jurjen, primary, Winkels, Gregor, primary, Petry, Katja, primary, Blokx, Willeke A.M., primary, van Rossum, Michelle M., primary, Welzen, Marieke E.B., primary, Mus, Roel D.M., primary, Croockewit, Sandra A.J., primary, Koornstra, Rutger H.T., primary, Jacobs, Joannes F.M., primary, Kelderman, Sander, primary, Blank, Christian U., primary, Gerritsen, Winald R., primary, Punt, Cornelis J.A., primary, Figdor, Carl G., primary, and de Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure 2 from Route of Administration Modulates the Induction of Dendritic Cell Vaccine–Induced Antigen-Specific T Cells in Advanced Melanoma Patients

Author

Lesterhuis, W. Joost, primary, de Vries, I. Jolanda M., primary, Schreibelt, Gerty, primary, Lambeck, Annechien J.A., primary, Aarntzen, Erik H.J.G., primary, Jacobs, Joannes F.M., primary, Scharenborg, Nicole M., primary, van de Rakt, Mandy W.M.M., primary, de Boer, Annemiek J., primary, Croockewit, Sandra, primary, van Rossum, Michelle M., primary, Mus, Roel, primary, Oyen, Wim J.G., primary, Boerman, Otto C., primary, Lucas, Sophie, primary, Adema, Gosse J., primary, Punt, Cornelis J.A., primary, and Figdor, Carl G., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 1 from Route of Administration Modulates the Induction of Dendritic Cell Vaccine–Induced Antigen-Specific T Cells in Advanced Melanoma Patients

Author

Lesterhuis, W. Joost, primary, de Vries, I. Jolanda M., primary, Schreibelt, Gerty, primary, Lambeck, Annechien J.A., primary, Aarntzen, Erik H.J.G., primary, Jacobs, Joannes F.M., primary, Scharenborg, Nicole M., primary, van de Rakt, Mandy W.M.M., primary, de Boer, Annemiek J., primary, Croockewit, Sandra, primary, van Rossum, Michelle M., primary, Mus, Roel, primary, Oyen, Wim J.G., primary, Boerman, Otto C., primary, Lucas, Sophie, primary, Adema, Gosse J., primary, Punt, Cornelis J.A., primary, and Figdor, Carl G., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 1 from Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients

Author

Aarntzen, Erik H. J. G., primary, Schreibelt, Gerty, primary, Bol, Kalijn, primary, Lesterhuis, W. Joost, primary, Croockewit, Alexandra J., primary, de Wilt, Johannes H. W., primary, van Rossum, Michelle M., primary, Blokx, Willeke A. M., primary, Jacobs, Joannes F. M., primary, Duiveman-de Boer, Tjitske, primary, Schuurhuis, Danita H., primary, Mus, Roel, primary, Thielemans, Kris, primary, de Vries, I. Jolanda M., primary, Figdor, Carl G., primary, Punt, Cornelis J. A., primary, and Adema, Gosse J., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 1 from Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells

Author

Schreibelt, Gerty, primary, Bol, Kalijn F., primary, Westdorp, Harm, primary, Wimmers, Florian, primary, Aarntzen, Erik H.J.G., primary, Duiveman-de Boer, Tjitske, primary, van de Rakt, Mandy W.M.M., primary, Scharenborg, Nicole M., primary, de Boer, Annemiek J., primary, Pots, Jeanette M., primary, Olde Nordkamp, Michel A.M., primary, van Oorschot, Tom G.M., primary, Tel, Jurjen, primary, Winkels, Gregor, primary, Petry, Katja, primary, Blokx, Willeke A.M., primary, van Rossum, Michelle M., primary, Welzen, Marieke E.B., primary, Mus, Roel D.M., primary, Croockewit, Sandra A.J., primary, Koornstra, Rutger H.T., primary, Jacobs, Joannes F.M., primary, Kelderman, Sander, primary, Blank, Christian U., primary, Gerritsen, Winald R., primary, Punt, Cornelis J.A., primary, Figdor, Carl G., primary, and de Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 4 from Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell–Based Vaccination in Metastatic Melanoma

Author

Aarntzen, Erik H.J.G., primary, Bol, Kalijn, primary, Schreibelt, Gerty, primary, Jacobs, Joannes F.M., primary, Lesterhuis, W. Joost, primary, Van Rossum, Michelle M., primary, Adema, Gosse J., primary, Figdor, Carl G., primary, Punt, Cornelis J.A., primary, and De Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Table 1 from Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell–Based Vaccination

Author

Aarntzen, Erik H.J.G., primary, De Vries, I. Jolanda M., primary, Lesterhuis, W. Joost, primary, Schuurhuis, Danita, primary, Jacobs, Joannes F.M., primary, Bol, Kalijn, primary, Schreibelt, Gerty, primary, Mus, Roel, primary, De Wilt, Johannes H.W., primary, Haanen, John B.A.G., primary, Schadendorf, Dirk, primary, Croockewit, Alexandra, primary, Blokx, Willeke A.M., primary, Van Rossum, Michelle M., primary, Kwok, William W., primary, Adema, Gosse J., primary, Punt, Cornelis J.A., primary, and Figdor, Carl G., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 5 from Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell–Based Vaccination in Metastatic Melanoma

Author

Aarntzen, Erik H.J.G., primary, Bol, Kalijn, primary, Schreibelt, Gerty, primary, Jacobs, Joannes F.M., primary, Lesterhuis, W. Joost, primary, Van Rossum, Michelle M., primary, Adema, Gosse J., primary, Figdor, Carl G., primary, Punt, Cornelis J.A., primary, and De Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 3 from Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell–Based Vaccination in Metastatic Melanoma

Author

Aarntzen, Erik H.J.G., primary, Bol, Kalijn, primary, Schreibelt, Gerty, primary, Jacobs, Joannes F.M., primary, Lesterhuis, W. Joost, primary, Van Rossum, Michelle M., primary, Adema, Gosse J., primary, Figdor, Carl G., primary, Punt, Cornelis J.A., primary, and De Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Legends for Figures 1-3, Table 1 from Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell–Based Vaccination

Author

Aarntzen, Erik H.J.G., primary, De Vries, I. Jolanda M., primary, Lesterhuis, W. Joost, primary, Schuurhuis, Danita, primary, Jacobs, Joannes F.M., primary, Bol, Kalijn, primary, Schreibelt, Gerty, primary, Mus, Roel, primary, De Wilt, Johannes H.W., primary, Haanen, John B.A.G., primary, Schadendorf, Dirk, primary, Croockewit, Alexandra, primary, Blokx, Willeke A.M., primary, Van Rossum, Michelle M., primary, Kwok, William W., primary, Adema, Gosse J., primary, Punt, Cornelis J.A., primary, and Figdor, Carl G., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure 2 from Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell–Based Vaccination in Metastatic Melanoma

Author

Aarntzen, Erik H.J.G., primary, Bol, Kalijn, primary, Schreibelt, Gerty, primary, Jacobs, Joannes F.M., primary, Lesterhuis, W. Joost, primary, Van Rossum, Michelle M., primary, Adema, Gosse J., primary, Figdor, Carl G., primary, Punt, Cornelis J.A., primary, and De Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure 3 from Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell–Based Vaccination

Author

Aarntzen, Erik H.J.G., primary, De Vries, I. Jolanda M., primary, Lesterhuis, W. Joost, primary, Schuurhuis, Danita, primary, Jacobs, Joannes F.M., primary, Bol, Kalijn, primary, Schreibelt, Gerty, primary, Mus, Roel, primary, De Wilt, Johannes H.W., primary, Haanen, John B.A.G., primary, Schadendorf, Dirk, primary, Croockewit, Alexandra, primary, Blokx, Willeke A.M., primary, Van Rossum, Michelle M., primary, Kwok, William W., primary, Adema, Gosse J., primary, Punt, Cornelis J.A., primary, and Figdor, Carl G., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure Legends 1-5 from Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell–Based Vaccination in Metastatic Melanoma

Author

Aarntzen, Erik H.J.G., primary, Bol, Kalijn, primary, Schreibelt, Gerty, primary, Jacobs, Joannes F.M., primary, Lesterhuis, W. Joost, primary, Van Rossum, Michelle M., primary, Adema, Gosse J., primary, Figdor, Carl G., primary, Punt, Cornelis J.A., primary, and De Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure 2 from Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell–Based Vaccination

Author

Aarntzen, Erik H.J.G., primary, De Vries, I. Jolanda M., primary, Lesterhuis, W. Joost, primary, Schuurhuis, Danita, primary, Jacobs, Joannes F.M., primary, Bol, Kalijn, primary, Schreibelt, Gerty, primary, Mus, Roel, primary, De Wilt, Johannes H.W., primary, Haanen, John B.A.G., primary, Schadendorf, Dirk, primary, Croockewit, Alexandra, primary, Blokx, Willeke A.M., primary, Van Rossum, Michelle M., primary, Kwok, William W., primary, Adema, Gosse J., primary, Punt, Cornelis J.A., primary, and Figdor, Carl G., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure 1 from Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell–Based Vaccination

Author

Aarntzen, Erik H.J.G., primary, De Vries, I. Jolanda M., primary, Lesterhuis, W. Joost, primary, Schuurhuis, Danita, primary, Jacobs, Joannes F.M., primary, Bol, Kalijn, primary, Schreibelt, Gerty, primary, Mus, Roel, primary, De Wilt, Johannes H.W., primary, Haanen, John B.A.G., primary, Schadendorf, Dirk, primary, Croockewit, Alexandra, primary, Blokx, Willeke A.M., primary, Van Rossum, Michelle M., primary, Kwok, William W., primary, Adema, Gosse J., primary, Punt, Cornelis J.A., primary, and Figdor, Carl G., primary

Published
2023
Full Text
View/download PDF

27. Data from Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell–Based Vaccination

Author

Aarntzen, Erik H.J.G., primary, De Vries, I. Jolanda M., primary, Lesterhuis, W. Joost, primary, Schuurhuis, Danita, primary, Jacobs, Joannes F.M., primary, Bol, Kalijn, primary, Schreibelt, Gerty, primary, Mus, Roel, primary, De Wilt, Johannes H.W., primary, Haanen, John B.A.G., primary, Schadendorf, Dirk, primary, Croockewit, Alexandra, primary, Blokx, Willeke A.M., primary, Van Rossum, Michelle M., primary, Kwok, William W., primary, Adema, Gosse J., primary, Punt, Cornelis J.A., primary, and Figdor, Carl G., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure 1 from Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell–Based Vaccination in Metastatic Melanoma

Author

Aarntzen, Erik H.J.G., primary, Bol, Kalijn, primary, Schreibelt, Gerty, primary, Jacobs, Joannes F.M., primary, Lesterhuis, W. Joost, primary, Van Rossum, Michelle M., primary, Adema, Gosse J., primary, Figdor, Carl G., primary, Punt, Cornelis J.A., primary, and De Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

30. Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity

Author

Bol, Kalijn F., Aarntzen, Erik H. J. G., Pots, Jeanette M., Olde Nordkamp, Michel A. M., van de Rakt, Mandy W. M. M., Scharenborg, Nicole M., de Boer, Annemiek J., van Oorschot, Tom G. M., Croockewit, Sandra A. J., Blokx, Willeke A. M., Oyen, Wim J. G., Boerman, Otto C., Mus, Roel D. M., van Rossum, Michelle M., van der Graaf, Chantal A. A., Punt, Cornelis J. A., Adema, Gosse J., Figdor, Carl G., de Vries, I. Jolanda M., and Schreibelt, Gerty

Published
2016
Full Text
View/download PDF

33. Trends in three major histological subtypes of cutaneous melanoma in the Netherlands between 1989 and 2016.

Author

van Niekerk, Catharina C., Otten, J. Hans D. M., van Rossum, Michelle M., van den Reek, Juul M. P. A., Brummelkamp, Erik, Mol, Martijn, Groenewoud, J. Hans M. M., and Verbeek, André L. M.

Subjects
COHORT analysis, TREND analysis, LENTIGO, MELANOMA
Abstract

Background: Time trend analysis of cutaneous melanoma (CM) mortality in fair skin populations shows both a gradual decrease and/or an increase. To explain these differences, we analyzed long‐term time trends in the incidence of the most common histological subtypes of CM: superficial spreading melanoma (SSM), lentigo maligna melanoma (LMM), and nodular melanoma (NM). Methods: Using data from the Netherlands Cancer Registry and Statistics Netherlands, the number and rates of cases diagnosed with SSM, LLM, and NM from 1989 to 2016 were analyzed by age, calendar period, and birth cohort of people born in successive periods from 1925 to 1973. Results: Primary CM was diagnosed in 52,000 men and 66,588 women in the study period. The annual age‐standardized incidence rate increased three‐fold from 14 to 42 per 100,000 person‐years. The most common subtype was SSM (50%), followed by LMM (23%) and NM (14%). Age‐specific subtype rates showed an upward trend over time for both men and women. Younger birth cohorts had higher rates of SSM and LMM diagnosis than older birth cohorts. This birth cohort pattern was not observed for NM. Conclusions: We observed a strong increase in the melanoma epidemic curves in the light‐skinned Dutch population over the last three decades. This increase is explained by younger generations having higher rates of SSM and LMM than older generations. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

34. Early identification of antigen-specific immune responses in vivo by [¹ɸF]-labeled 3'-fluoro-3'-deoxy-thymidine ([¹ɸF] FLT) PET imaging

Author

Aarntzen, Erik H. J. G., Srinivas, Mangala, De Wilt, Johannes H. W., Jacobs, Joannes F. M., Lesterhuis, W. Joost, Windhorst, Albert D., Troost, Esther G., Bonenkamp, Johannes J., van Rossum, Michelle M., Blokx, Willeke A. M., Mus, Roel D., Boerman, Otto C., Punt, Cornelis J. A., Figdor, Carl G., Oyen, Wim J. G., and de Vries, I. Jolanda M.

Published
2011

35. Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients

Author

Bloemendal, Martine, primary, Bol, Kalijn F., additional, Boudewijns, Steve, additional, Gorris, Mark A.J., additional, de Wilt, Johannes H.W., additional, Croockewit, Sandra A.J., additional, van Rossum, Michelle M., additional, de Goede, Anna L., additional, Petry, Katja, additional, Koornstra, Rutger H.T., additional, Figdor, Carl, additional, Gerritsen, Winald R., additional, Schreibelt, Gerty, additional, and de Vries, I. Jolanda M., additional

Published
2021
Full Text
View/download PDF

36. Outcomes of rare patients with a primary cutaneous CD30+ lymphoproliferative disorder developing extracutaneous disease

Author

Melchers, Rutger C., primary, Willemze, Rein, primary, Vermaat, Joost S. P., primary, Jansen, Patty M., primary, Daniëls, Laurien A., primary, Putter, Hein, primary, Bekkenk, Marcel W., primary, de Haas, Ellen R. M., primary, Horvath, Barbara, primary, van Rossum, Michelle M., primary, Sanders, Cornelus J. G., primary, Veraart, Joep C. J. M., primary, Vermeer, Maarten H., primary, and Quint, Koen D., primary

Published
2020
Full Text
View/download PDF

38. Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients.

Author

Bloemendal, Martine, Bol, Kalijn F., Boudewijns, Steve, Gorris, Mark A. J., de Wilt, Johannes H. W., Croockewit, Sandra A. J., van Rossum, Michelle M., de Goede, Anna L., Petry, Katja, Koornstra, Rutger H. T., Figdor, Carl, Gerritsen, Winald R., Schreibelt, Gerty, and de Vries, I. Jolanda M.

Subjects
DENDRITIC cells, IMMUNOLOGICAL adjuvants, MYELOID cells, VACCINATION, MELANOMA
Abstract

We evaluated the immunological responses of lymph-node involved (stage III) melanoma patients to adjuvant dendritic cell vaccination with subsets of naturally occurring dendritic cells (nDCs). Fifteen patients with completely resected stage III melanoma were randomized to receive adjuvant dendritic cell vaccination with CD1c+ myeloid dendritic cells (cDC2s), plasmacytoid dendritic cells (pDCs) or the combination. Immunological response was the primary endpoint and secondary endpoints included safety and survival. In 80% of the patients, antigen-specific CD8+ T cells were detected in skin test-derived T cells and in 55% of patients, antigen-specific CD8+ T cells were detectable in peripheral blood. Functional interferon-γ-producing T cells were found in the skin test of 64% of the patients. Production of nDC vaccines meeting release criteria was feasible for all patients. Vaccination only induced grade 1-2 adverse events, mainly consisting of fatigue. In conclusion, adjuvant dendritic cell vaccination with cDC2s and/or pDCs is feasible, safe and induced immunological responses in the majority of stage III melanoma patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

41. Allelic Mutations of KITLG, Encoding KIT Ligand, Cause Asymmetric and Unilateral Hearing Loss and Waardenburg Syndrome Type 2

Author

Zazo Seco, Celia, Serrão de Castro, Luciana, van Nierop, Josephine W, Morín, Matías, Jhangiani, Shalini, Verver, Eva J J, Schraders, Margit, Maiwald, Nadine, Wesdorp, Mieke, Venselaar, Hanka, Spruijt, Liesbeth, Oostrik, Jaap, Schoots, Jeroen, van Reeuwijk, Jeroen, Lelieveld, Stefan H, Huygen, Patrick L M, Insenser, María, Admiraal, Ronald J C, Pennings, Ronald J E, Hoefsloot, Lies H, Arias-Vásquez, Alejandro, de Ligt, Joep, Yntema, Helger G, Jansen, Joop H, Muzny, Donna M, Huls, Gerwin, van Rossum, Michelle M, Lupski, James R, Moreno-Pelayo, Miguel Angel, Kunst, Henricus P M, and Kremer, Hannie

Subjects
Male, Stem Cell Factor, Reverse Transcriptase Polymerase Chain Reaction, Genetic Linkage, Fluorescent Antibody Technique, Hearing Loss, Unilateral, Prognosis, Real-Time Polymerase Chain Reaction, Pedigree, Mice, Phenotype, Mutation, NIH 3T3 Cells, Animals, Humans, Female, Waardenburg Syndrome, RNA, Messenger, Alleles
Abstract

Linkage analysis combined with whole-exome sequencing in a large family with congenital and stable non-syndromic unilateral and asymmetric hearing loss (NS-UHL/AHL) revealed a heterozygous truncating mutation, c.286_303delinsT (p.Ser96Ter), in KITLG. This mutation co-segregated with NS-UHL/AHL as a dominant trait with reduced penetrance. By screening a panel of probands with NS-UHL/AHL, we found an additional mutation, c.200_202del (p.His67_Cys68delinsArg). In vitro studies revealed that the p.His67_Cys68delinsArg transmembrane isoform of KITLG is not detectable at the cell membrane, supporting pathogenicity. KITLG encodes a ligand for the KIT receptor. Also, KITLG-KIT signaling and MITF are suggested to mutually interact in melanocyte development. Because mutations in MITF are causative of Waardenburg syndrome type 2 (WS2), we screened KITLG in suspected WS2-affected probands. A heterozygous missense mutation, c.310C>G (p.Leu104Val), that segregated with WS2 was identified in a small family. In vitro studies revealed that the p.Leu104Val transmembrane isoform of KITLG is located at the cell membrane, as is wild-type KITLG. However, in culture media of transfected cells, the p.Leu104Val soluble isoform of KITLG was reduced, and no soluble p.His67_Cys68delinsArg and p.Ser96Ter KITLG could be detected. These data suggest that mutations in KITLG associated with NS-UHL/AHL have a loss-of-function effect. We speculate that the mechanism of the mutation underlying WS2 and leading to membrane incorporation and reduced secretion of KITLG occurs via a dominant-negative or gain-of-function effect. Our study unveils different phenotypes associated with KITLG, previously associated with pigmentation abnormalities, and will thereby improve the genetic counseling given to individuals with KITLG variants.

Published
2015

43. Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma

Author

Bol, Kalijn F., primary, van den Bosch, Thomas, additional, Schreibelt, Gerty, additional, Mensink, Hanneke W., additional, Keunen, Jan E.E., additional, Kiliç, Emine, additional, Japing, Wouter J., additional, Geul, Kaspar W., additional, Westdorp, Harm, additional, Boudewijns, Steve, additional, Croockewit, Sandra A.J., additional, van Rossum, Michelle M., additional, de Goede, Anna L., additional, Naus, Nicole C., additional, van der Graaf, Winette T.A., additional, Gerritsen, Winald R., additional, de Klein, Annelies, additional, Punt, Cornelis J.A., additional, Figdor, Carl G., additional, Cohen, Victoria M., additional, Paridaens, Dion, additional, and de Vries, I. Jolanda M., additional

Published
2016
Full Text
View/download PDF

44. Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients

Author

Boudewijns, Steve, primary, Bol, Kalijn F., additional, Schreibelt, Gerty, additional, Westdorp, Harm, additional, Textor, Johannes C., additional, van Rossum, Michelle M., additional, Scharenborg, Nicole M., additional, de Boer, Annemiek J., additional, van de Rakt, Mandy W. M. M., additional, Pots, Jeanne M., additional, van Oorschot, Tom G. M., additional, Duiveman-de Boer, Tjitske, additional, Olde Nordkamp, Michel A., additional, van Meeteren, Wilmy S. E. C., additional, van der Graaf, Winette T. A., additional, Bonenkamp, Johannes J., additional, de Wilt, Johannes H. W., additional, Aarntzen, Erik H. J. G., additional, Punt, Cornelis J. A., additional, Gerritsen, Winald R., additional, Figdor, Carl G., additional, and de Vries, I. Jolanda M., additional

Published
2016
Full Text
View/download PDF

45. Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells

Author

Schreibelt, Gerty, primary, Bol, Kalijn F., additional, Westdorp, Harm, additional, Wimmers, Florian, additional, Aarntzen, Erik H.J.G., additional, Duiveman-de Boer, Tjitske, additional, van de Rakt, Mandy W.M.M., additional, Scharenborg, Nicole M., additional, de Boer, Annemiek J., additional, Pots, Jeanette M., additional, Olde Nordkamp, Michel A.M., additional, van Oorschot, Tom G.M., additional, Tel, Jurjen, additional, Winkels, Gregor, additional, Petry, Katja, additional, Blokx, Willeke A.M., additional, van Rossum, Michelle M., additional, Welzen, Marieke E.B., additional, Mus, Roel D.M., additional, Croockewit, Sandra A.J., additional, Koornstra, Rutger H.T., additional, Jacobs, Joannes F.M., additional, Kelderman, Sander, additional, Blank, Christian U., additional, Gerritsen, Winald R., additional, Punt, Cornelis J.A., additional, Figdor, Carl G., additional, and de Vries, I. Jolanda M., additional

Published
2016
Full Text
View/download PDF

46. Allelic Mutations of KITLG, Encoding KIT Ligand, Cause Asymmetric and Unilateral Hearing Loss and Waardenburg Syndrome Type 2

Author

Zazo Seco, Celia, primary, Serrão de Castro, Luciana, additional, van Nierop, Josephine W., additional, Morín, Matías, additional, Jhangiani, Shalini, additional, Verver, Eva J.J., additional, Schraders, Margit, additional, Maiwald, Nadine, additional, Wesdorp, Mieke, additional, Venselaar, Hanka, additional, Spruijt, Liesbeth, additional, Oostrik, Jaap, additional, Schoots, Jeroen, additional, van Reeuwijk, Jeroen, additional, Lelieveld, Stefan H., additional, Huygen, Patrick L.M., additional, Insenser, María, additional, Admiraal, Ronald J.C., additional, Pennings, Ronald J.E., additional, Hoefsloot, Lies H., additional, Arias-Vásquez, Alejandro, additional, de Ligt, Joep, additional, Yntema, Helger G., additional, Jansen, Joop H., additional, Muzny, Donna M., additional, Huls, Gerwin, additional, van Rossum, Michelle M., additional, Lupski, James R., additional, Moreno-Pelayo, Miguel Angel, additional, Kunst, Henricus P.M., additional, and Kremer, Hannie, additional

Published
2015
Full Text
View/download PDF

47. Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients

Author

Bol, Kalijn F, primary, Figdor, Carl G, additional, Aarntzen, Erik HJG, additional, Welzen, Marieke EB, additional, van Rossum, Michelle M, additional, Blokx, Willeke AM, additional, van de Rakt, Mandy WMM, additional, Scharenborg, Nicole M, additional, de Boer, Annemiek J, additional, Pots, Jeanette M, additional, olde Nordkamp, Michel AM, additional, van Oorschot, Tom GM, additional, Mus, Roel DM, additional, Croockewit, Sandra AJ, additional, Jacobs, Joannes FM, additional, Schuler, Gerold, additional, Neyns, Bart, additional, Austyn, Jonathan M, additional, Punt, Cornelis JA, additional, Schreibelt, Gerty, additional, and de Vries, I Jolanda M, additional

Published
2015
Full Text
View/download PDF

49. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility.

Author

Stacey, Simon N, Sulem, Patrick, Jonasdottir, Aslaug, Masson, Gisli, Gudmundsson, Julius, Gudbjartsson, Daniel F, Magnusson, Olafur T, Gudjonsson, Sigurjon A, Sigurgeirsson, Bardur, Thorisdottir, Kristin, Ragnarsson, Rafn, Benediktsdottir, Kristrun R, Nexø, Bjørn A, Tjønneland, Anne, Overvad, Kim, Rudnai, Peter, Gurzau, Eugene, Koppova, Kvetoslava, Hemminki, Kari, Corredera, Cristina, Fuentelsaz, Victoria, Grasa, Pilar, Navarrete, Sebastian, Fuertes, Fernando, García-Prats, Maria D, Sanambrosio, Enrique, Panadero, Angeles, De Juan, Ana, Garcia, Almudena, Rivera, Fernando, Planelles, Dolores, Soriano, Virtudes, Requena, Celia, Aben, Katja K, van Rossum, Michelle M, Cremers, Ruben G H M, van Oort, Inge M, van Spronsen, Dick-Johan, Schalken, Jack A, Peters, Wilbert H M, Helfand, Brian T, Donovan, Jenny L, Hamdy, Freddie C, Badescu, Daniel, Codreanu, Ovidiu, Jinga, Mariana, Csiki, Irma E, Constantinescu, Vali, Badea, Paula, Mates, Ioan N, Dinu, Daniela E, Constantin, Adrian, Mates, Dana, Kristjansdottir, Sjofn, Agnarsson, Bjarni A, Jonsson, Eirikur, Barkardottir, Rosa B, Einarsson, Gudmundur V, Sigurdsson, Fridbjorn, Moller, Pall H, Stefansson, Tryggvi, Valdimarsson, Trausti, Johannsson, Oskar T, Sigurdsson, Helgi, Jonsson, Thorvaldur, Jonasson, Jon G, Tryggvadottir, Laufey, Rice, Terri, Hansen, Helen M, Xiao, Yuanyuan, Lachance, Daniel H, O Neill, Brian Patrick, Kosel, Matthew L, Decker, Paul A, Thorleifsson, Gudmar, Johannsdottir, Hrefna, Helgadottir, Hafdis T, Sigurdsson, Asgeir, Steinthorsdottir, Valgerdur, Lindblom, Annika, Sandler, Robert S, Keku, Temitope O, Banasik, Karina, Jørgensen, Torben, Witte, Daniel R, Hansen, Torben, Pedersen, Oluf, Jinga, Viorel, Neal, David E, Catalona, William J, Wrensch, Margaret, Wiencke, John, Jenkins, Robert B, Nagore, Eduardo, Vogel, Ulla, Kiemeney, Lambertus A, Kumar, Rajiv, Mayordomo, José I, Olafsson, Jon H, Kong, Augustine, Thorsteinsdottir, Unnur, Rafnar, Thorunn, Stefansson, Kari, Smedh, Kenneth, Stacey, Simon N, Sulem, Patrick, Jonasdottir, Aslaug, Masson, Gisli, Gudmundsson, Julius, Gudbjartsson, Daniel F, Magnusson, Olafur T, Gudjonsson, Sigurjon A, Sigurgeirsson, Bardur, Thorisdottir, Kristin, Ragnarsson, Rafn, Benediktsdottir, Kristrun R, Nexø, Bjørn A, Tjønneland, Anne, Overvad, Kim, Rudnai, Peter, Gurzau, Eugene, Koppova, Kvetoslava, Hemminki, Kari, Corredera, Cristina, Fuentelsaz, Victoria, Grasa, Pilar, Navarrete, Sebastian, Fuertes, Fernando, García-Prats, Maria D, Sanambrosio, Enrique, Panadero, Angeles, De Juan, Ana, Garcia, Almudena, Rivera, Fernando, Planelles, Dolores, Soriano, Virtudes, Requena, Celia, Aben, Katja K, van Rossum, Michelle M, Cremers, Ruben G H M, van Oort, Inge M, van Spronsen, Dick-Johan, Schalken, Jack A, Peters, Wilbert H M, Helfand, Brian T, Donovan, Jenny L, Hamdy, Freddie C, Badescu, Daniel, Codreanu, Ovidiu, Jinga, Mariana, Csiki, Irma E, Constantinescu, Vali, Badea, Paula, Mates, Ioan N, Dinu, Daniela E, Constantin, Adrian, Mates, Dana, Kristjansdottir, Sjofn, Agnarsson, Bjarni A, Jonsson, Eirikur, Barkardottir, Rosa B, Einarsson, Gudmundur V, Sigurdsson, Fridbjorn, Moller, Pall H, Stefansson, Tryggvi, Valdimarsson, Trausti, Johannsson, Oskar T, Sigurdsson, Helgi, Jonsson, Thorvaldur, Jonasson, Jon G, Tryggvadottir, Laufey, Rice, Terri, Hansen, Helen M, Xiao, Yuanyuan, Lachance, Daniel H, O Neill, Brian Patrick, Kosel, Matthew L, Decker, Paul A, Thorleifsson, Gudmar, Johannsdottir, Hrefna, Helgadottir, Hafdis T, Sigurdsson, Asgeir, Steinthorsdottir, Valgerdur, Lindblom, Annika, Sandler, Robert S, Keku, Temitope O, Banasik, Karina, Jørgensen, Torben, Witte, Daniel R, Hansen, Torben, Pedersen, Oluf, Jinga, Viorel, Neal, David E, Catalona, William J, Wrensch, Margaret, Wiencke, John, Jenkins, Robert B, Nagore, Eduardo, Vogel, Ulla, Kiemeney, Lambertus A, Kumar, Rajiv, Mayordomo, José I, Olafsson, Jon H, Kong, Augustine, Thorsteinsdottir, Unnur, Rafnar, Thorunn, Stefansson, Kari, and Smedh, Kenneth

Abstract

To identify new risk variants for cutaneous basal cell carcinoma, we performed a genome-wide association study of 16 million SNPs identified through whole-genome sequencing of 457 Icelanders. We imputed genotypes for 41,675 Illumina SNP chip-typed Icelanders and their relatives. In the discovery phase, the strongest signal came from rs78378222[C] (odds ratio (OR) = 2.36, P = 5.2 × 10(-17)), which has a frequency of 0.0192 in the Icelandic population. We then confirmed this association in non-Icelandic samples (OR = 1.75, P = 0.0060; overall OR = 2.16, P = 2.2 × 10(-20)). rs78378222 is in the 3' untranslated region of TP53 and changes the AATAAA polyadenylation signal to AATACA, resulting in impaired 3'-end processing of TP53 mRNA. Investigation of other tumor types identified associations of this SNP with prostate cancer (OR = 1.44, P = 2.4 × 10(-6)), glioma (OR = 2.35, P = 1.0 × 10(-5)) and colorectal adenoma (OR = 1.39, P = 1.6 × 10(-4)). However, we observed no effect for breast cancer, a common Li-Fraumeni syndrome tumor (OR = 1.06, P = 0.57, 95% confidence interval 0.88-1.27).

Published
2011
Full Text
View/download PDF

50. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.

Author

UCL - SSS/DDUV - Institut de Duve, Lesterhuis, W Joost, de Vries, I Jolanda M, Schreibelt, Gerty, Lambeck, Annechien J A, Aarntzen, Erik H J G, Jacobs, Joannes F M, Scharenborg, Nicole M, van de Rakt, Mandy W M M, de Boer, Annemiek J, Croockewit, Sandra, van Rossum, Michelle M, Mus, Roel, Oyen, Wim J G, Boerman, Otto C, Lucas, Sophie, Adema, Gosse J, Punt, Cornelis J A, Figdor, Carl G, UCL - SSS/DDUV - Institut de Duve, Lesterhuis, W Joost, de Vries, I Jolanda M, Schreibelt, Gerty, Lambeck, Annechien J A, Aarntzen, Erik H J G, Jacobs, Joannes F M, Scharenborg, Nicole M, van de Rakt, Mandy W M M, de Boer, Annemiek J, Croockewit, Sandra, van Rossum, Michelle M, Mus, Roel, Oyen, Wim J G, Boerman, Otto C, Lucas, Sophie, Adema, Gosse J, Punt, Cornelis J A, and Figdor, Carl G

Abstract

Intradermal vaccination resulted in superior antitumor T-cell induction when compared with intranodal vaccination. No advantage of additional IL-2 treatment could be shown.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results